Jörg T Kley

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure
    Jörg T Kley
    Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 65, D 88397 Biberach, Germany
    Bioorg Med Chem Lett 21:5924-7. 2011

Detail Information

Publications1

  1. ncbi Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure
    Jörg T Kley
    Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 65, D 88397 Biberach, Germany
    Bioorg Med Chem Lett 21:5924-7. 2011
    ..Optimisation yielded BI 99179 which is characterised by high potency, remarkably high selectivity and significant exposure (both peripheral and central) upon oral administration in rats...